Drug intelligence / Profile preview

STC2607

Development stage: Unknown
Lead developer: Staidson Biopharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

STC2607 is a monoclonal antibody developed by Staidson Pharma (Staidson Hongkong) that targets the interleukin-4 receptor alpha (IL-4Rα). By binding to IL-4Rα, STC2607 acts as an antagonist to block the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), which are key type 2 cytokines involved in the pathogenesis of allergic and inflammatory diseases. The drug is currently in Phase 1 clinical development for the treatment of asthma and atopic dermatitis, aiming to provide a therapeutic option for conditions driven by type 2 inflammation.

Targets

IL4R (Interleukin-4 receptor alpha subunit)

Beyond the preview

Go deeper on STC2607.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STC2607.

Explore the full profile